Veerhealth Care — Initiating Coverage (BUY)

Rating snapshot

Business overview

Veerhealth Care is a BSE-listed maker of Ayurvedic and cosmetic formulations, with its plant in Vapi, Gujarat. Originally incorporated in 1992 as Niyati Leasing, it pivoted to Ayurvedic and herbal cosmetics in 2013. It earns through contract manufacturing for large brands, its own D2C brand Ayuveer, and a young hospital-equipment business.

• Ayurvedic & herbal medicine — oral liquids, tablets, powders and ointments, including high-volume contract work such as gripe water. Clients include Apollo Pharmacy, davaindia, Godrej Consumer Products, BobBarker, Zota Healthcare and Sakar Healthcare.
• Cosmetics & personal care — 42 product lines across hair, skin, body and oral care, sold under Ayuveer and made for pharmacy chains. A strength is pure-vegetarian herbal toothpaste, a major export driver.
• Disinfectants — floor cleaners and fabric disinfectants for private-label clients.
• Hospital Care (launched December 2024) — ventilators, defibrillators and infusion pumps supplied with critical-care partners; the first batch has gone to a government organisation.

Backward integration supports margins: the in-house Veer Plast division moulds bottles, containers, jars and caps, and brush tufting machinery lets the company supply toothpaste and toothbrushes from one site.

Industry & competitive position

India's AYUSH manufacturing segment grew from USD 18 billion in 2020 to USD 24 billion in 2024, and IMARC projects ~17% CAGR over 2024–2032. The cosmetics and personal-care market is about USD 23.7 billion (2025), with herbal "clean beauty" a direct tailwind for Veerhealth.

• USFDA clearance — very few small-caps hold a USFDA-cleared plant, which lets Veerhealth pitch for export and large institutional orders instead of competing on price alone.
• Sticky clients — onboarding by pharmacy chains takes multi-year audits and product qualification, so relationships tend to repeat.
• Tariff advantage — lower US tariffs on Indian exports than on Chinese ones make its products roughly 20% cheaper for US buyers.

Growth levers

• Ayuveer brand — rebranding, new SKUs and wider e-commerce reach (Amazon, Flipkart, Nykaa, Myntra, JioMart). Management expects incremental Ayuveer sales of ~INR 2 Cr in FY27 and ~INR 5 Cr in FY28.
• Capacity expansion — the Vapi site grows from 60,000 to 90,000 sq. ft. to USFDA cGMP norms. A 5,000-litre mixer and automated lines take cosmetic output from ~50,000 to 1,10,000 bottles a day; liquid filling doubles to 2,000 litres a day; solar rises from 120 kW to 500 kW.
• Funding — ~INR 32 Cr through a preferential allotment (INR 20 Cr), bank term loan (INR 10 Cr) and internal accruals (INR 2 Cr).
• Order book — about INR 26.8 Cr of orders in FY27, including INR 10.08 Cr from a 125-year-old FMCG group, INR 2.93 Cr of body-care exports to a New York buyer, and a first order into Sudan.
• Pipeline — advanced talks with a Russian group for oral care exports, expected benefits from the India–EU trade deal, and a supply agreement with an Indo-Canadian hotel and airline amenities maker.

Financial analysis

FY27 and FY28 figures follow management guidance. Q1 FY27 supports it: revenue of INR 25.09 Cr (up 388% YoY), EBITDA of INR 2.07 Cr and PAT of INR 1.23 Cr (up 412% YoY). FY26 profit was held back by renovation disruption, a forex loss and a deferred tax provision.

Property, plant and equipment has roughly doubled in three years to INR 23.43 Cr. Borrowings are modest (~INR 4.6 Cr in FY26), and operating cash flow has been positive, with free cash flow expected to turn positive from FY27E as capex tapers.

Valuation

On FY27E PAT of INR 9.14 Cr and a one-year-forward P/E of 26x, the implied market cap is about INR 240 Cr against INR 99.9 Cr today — a target price of INR 120 and ~140% upside. The stock also trades below FMCG peers:

Key risks & things to track

• Execution on guidance — FY27E assumes ~4x revenue growth; capacity utilisation and fresh orders need to keep pace.
• Profitability margins as the business mix shifts.
• Working capital, which has been volatile in the past.
• Capital allocation and entry into new export markets.
• Traction for Ayuveer on online marketplaces.

Conclusion

Veerhealth Care is a niche player with near-term tailwinds: USFDA approval, government focus on AYUSH, and consumers moving towards natural products. After heavy capex it sits at an inflection point where earnings could follow a J-curve if management executes, and promoter participation in the warrant issue signals confidence. We initiate coverage with a BUY and a target price of INR 120.

Open the full report (PDF) 16 pages. On a phone, use the button to read the report.